Although the news about CytoDyn (CYDY) saying it could probably adapt its leronlimab drug to battle COVID-19, is two weeks old, the media finally caught up with the story when news that a small sample of patients with COVID-19 have responded positively to the drug treatment.In this article we’ll look at the potential opportunity this offers patients and CytoDyn, and also the many other diseases and conditions leronlimab could be useful for.Leronlimab and COVID-19The primary use and benefit of leronlimab is for patients having respiratory complications from COVID-19. At this time it is believed the treatment strengthens the “immune response mitigating the ‘cytokine storm’ that leads to morbidity and mortality in these patients.”Interim Chief Medical Officer of CytoDyn, Jacob Lalezari, M.D., said this about the